8-K: Teva Pharmaceutical Reports Strong 2023 Growth Driven by Key Brands and Strategic Collaborations

Teva Pharmaceutical Industries Ltd. announced a 7% revenue increase in local currency for 2023, driven by growth in key innovative brands and strategic collaborations.

Summary

• Teva Pharmaceutical Industries Ltd. reported a 7% increase in revenue in local currency terms for 2023, reaching $15.8 billion.
• The company's AUSTEDO product exceeded $1.2 billion in annual revenue, a 28% increase from 2022, with expectations to reach ~$1.5 billion in 2024.
• AJOVY global annual revenues reached $435 million, up 16% from 2022.
• The generics business stabilized and returned to revenue growth in Q4 2023.
• A $500 million upfront payment from a collaboration on an anti-TL1A asset contributed to the 2023 results.
• Net debt was reduced to $16.6 billion as of December 31, 2023.
• Teva is divesting its API business to focus on core strengths and growth engines.
• The company has entered into collaborations with Sanofi, Royalty Pharma, and Biolojic Design.
• The 2024 business outlook includes revenues of $15.7 $16.3 billion, non-GAAP operating income of $4.0-$4.5 billion, adjusted EBITDA of $4.5 $5.0 billion, non-GAAP diluted EPS of $2.20 $2.50, and free cash flow of $1.7 $2.0 billion.
• A revision of previously reported financial statements resulted in an understatement of $132 million in a contingent consideration liability, with $98 million related to 2022 and $34 million related to 2023.
• This revision did not impact non-GAAP results but led to the identification of a material weakness in internal controls.
• Free cash flow for 2023 was $2.387 billion, compared to $2.243 billion in 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key areas and strategic initiatives. However, there are some concerns regarding the revision of financial statements, internal control weaknesses, and the ongoing war in Israel. The positive aspects outweigh the negatives, leading to a sentiment score of 7.

Positives

• Teva achieved strong revenue growth in 2023, driven by key innovative brands.
• AUSTEDO's performance was exceptional, exceeding $1.2 billion in annual revenue.
• The generics business has stabilized and returned to growth.
• Strategic collaborations are contributing to revenue and pipeline development.
• The company is actively reducing its net debt.
• Teva's 'Pivot to Growth' strategy is showing positive results.
• The 2024 outlook is positive with expected revenue growth and strong profitability.
• Free cash flow generation is strong at $2.387 billion for 2023.

Negatives

• A revision of previously reported financial statements was required due to errors in a contingent consideration liability.
• A material weakness in internal controls over financial reporting was identified.
• The company experienced higher costs of goods sold due to inflationary and macroeconomic pressures.
• COPAXONE revenues continue to decline due to generic competition.
• Exchange rate movements negatively impacted revenues by $172 million, operating income by $111 million and non-GAAP operating income by $108 million in 2023.
• R&D expenses increased by 14% in 2023.

Risks

• The ongoing war in Israel could potentially impact Teva's operations and financial condition.
• The company faces risks related to competition, including generic competition for its products.
• Teva is subject to extensive pharmaceutical regulations and potential legal proceedings.
• The company's substantial indebtedness could limit its financial flexibility.
• There are risks associated with the divestiture of the API business, including timing and structure.
• Fluctuations in foreign exchange rates could negatively impact revenue and income.
• The company is exposed to credit risks and potential impairments of long-lived assets.

Future Outlook

Teva expects 2024 revenues of $15.7 $16.3 billion, non-GAAP operating income of $4.0-$4.5 billion, adjusted EBITDA of $4.5 $5.0 billion, non-GAAP diluted EPS of $2.20 $2.50, and free cash flow of $1.7 $2.0 billion. AUSTEDO is expected to generate ~$1.5 billion in revenue, AJOVY ~$500 million, UZEDY ~$80 million and COPAXONE ~$400 million.

Management Comments

• Richard Francis, Teva's President and CEO, stated that 2023 was a year of significant advances for Teva, with momentum gained on the 'Pivot to Growth' strategy.
• Mr. Francis highlighted strong growth in key innovative brands, accelerated late-stage pipeline assets, and the return of the generics business to growth.
• He also mentioned that in 2024, the company expects continued progress across key innovative growth drivers and the execution of the high-value, complex generics business.

Industry Context

Teva's results reflect a broader trend in the pharmaceutical industry where companies are focusing on innovative products and strategic collaborations to drive growth. The divestiture of the API business aligns with a trend of companies streamlining operations to focus on core competencies. The growth of AUSTEDO and AJOVY highlights the importance of specialty pharmaceuticals in the current market.

Comparison to Industry Standards

• Teva's 7% revenue growth in local currency terms is a solid performance compared to some of its generic peers, but lags behind some of the larger innovative pharmaceutical companies.
• The 28% growth in AUSTEDO revenues is impressive and positions it as a key growth driver, comparable to other successful specialty pharmaceutical products.
• The company's adjusted EBITDA margin of 27.5% is within the range of other large pharmaceutical companies, but there is room for improvement.
• The reduction in net debt is a positive sign, but the debt level remains high compared to some of its competitors.
• The divestiture of the API business is a strategic move similar to what other pharmaceutical companies have done to focus on higher-margin products.
• Teva's R&D spending at $953 million is significant, but it needs to translate into a robust pipeline of innovative products to compete with companies like AbbVie, Novartis, and Roche.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and positive outlook.
• Employees may be impacted by the divestiture of the API business.
• Customers will benefit from the continued availability of Teva's products.
• Suppliers may be affected by the divestiture of the API business.
• Creditors will be encouraged by the reduction in net debt.

Next Steps

• Teva will continue to execute its 'Pivot to Growth' strategy.
• The company will focus on expanding its innovative and biosimilar medicines pipeline.
• Teva will work to complete the divestiture of its API business in the first half of 2025.
• The company will continue to monitor the situation in Israel and its potential impact on operations.
• Teva will file its Annual Report on Form 10-K with the SEC.
• Teva will host a conference call to discuss its fourth quarter and annual 2023 results.

Key Dates

Keywords

Teva, Pharmaceutical, AUSTEDO, AJOVY, Generics, Revenue, Financial Results, Collaboration, Debt Reduction, API Divestiture, EBITDA, Free Cash Flow